![]() |
市场调查报告书
商品编码
1497663
生物标记市场:按产品/服务、类型、疾病、应用分类 - 全球预测 2024-2030Biomarkers Market by Product & Service (Consumables, Services, Software), Type (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers), Disease, Application - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年生物标记市场规模为525亿美元,预计2024年将达596.9亿美元,2030年将达到1329.8亿美元,复合年增长率为14.19%。
生物标记物也称为生物标誌物,是生物状况或状况的可测量指标,通常在体液和组织中被检测和量化。由于它可以反映各种生理和病理过程的存在,因此在医学领域中广泛应用,如诊断疾病、预测治疗效果、监测疾病进展等。生物标记的广泛使用主要是由于慢性病盛行率的不断上升以及对个人化医疗的日益重视,个人化医疗根据个人特征、行为和风险因素制定治疗方案。然而,生物标誌物开发的挑战包括发现和检验的高成本和复杂性、监管障碍以及需要强大的临床检验以确保可靠性和有效性。儘管存在这些挑战,针对新出现的健康威胁的新生物标誌物的开发、药物开发过程中对生物标誌物的关注以及人工智慧的整合以改善生物标誌物的发现和应用仍在继续,为更准确、更有效的医疗保健解决方案铺平了道路。
主要市场统计 | |
---|---|
基准年[2023] | 525亿美元 |
预测年份 [2024] | 596.9亿美元 |
预测年份 [2030] | 1329.8亿美元 |
复合年增长率(%) | 14.19% |
区域洞察
由于先进的医疗基础设施和研发投资,美洲生物标记市场呈现强劲成长。美国透过在临床实践中大规模采用生物标誌物以及对生物标誌物研究的强有力的机构支持,为这一增长做出了重大贡献。此外,慢性病盛行率的增加和对个人化医疗的浓厚兴趣是推动市场成长的主要因素。由于高额医疗保健支出和较早采用新技术,欧洲市场呈现稳定成长。由于医疗基础设施的改善以及对个人化医疗益处的认识不断提高,中东和非洲显示出成长潜力。由于经济的快速开拓、医疗保健支出的增加以及政府对医疗保健系统现代化的努力,亚太地区的生物标记市场呈现快速成长。人口增长和疾病发病率增加促进了生物标誌物的采用。此外,该地区生物技术公司和研究机构的扩张进一步支持了成长。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在生物标记物市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对生物标记物市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在生物标誌物市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[195 Pages Report] The Biomarkers Market size was estimated at USD 52.50 billion in 2023 and expected to reach USD 59.69 billion in 2024, at a CAGR 14.19% to reach USD 132.98 billion by 2030.
Biomarkers, also known as biological markers, a measurable indicators of some biological state or condition, often detected and quantified in body fluids or tissues. They are extensively used in medical science for diagnosing diseases, predicting treatment response, and monitoring the progress of disease, owing to their ability to reflect the presence of various physiological or pathological processes. The expansion of their use is primarily driven by the increasing prevalence of chronic diseases and a growing appreciation for personalized medicine, which tailors treatment to individual characteristics, behaviors, and risk factors. However, challenges in biomarker development include the high cost and complexity of discovery and validation, along with regulatory hurdles and the necessity for robust clinical validation to ensure reliability and efficacy. Despite these challenges, the development of novel biomarkers for emerging health threats, enhanced focus on biomarkers in drug development processes, and the integration of artificial intelligence to improve biomarker discovery and application pave the way for more precise and effective healthcare solutions.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 52.50 billion |
Estimated Year [2024] | USD 59.69 billion |
Forecast Year [2030] | USD 132.98 billion |
CAGR (%) | 14.19% |
Regional Insights
The biomarker market in the Americas is showing robust growth, with the presence of advanced healthcare infrastructure and investment in research and development. The United States is the major contributor to this growth, driven by the large-scale implementation of biomarkers in clinical practices and strong support from government entities for biomarker research. Additionally, the increasing prevalence of chronic diseases and a strong focus on personalized medicine are major factors propelling market growth. Europe is displaying steady market growth owing to high healthcare spending and early adoption of new technologies. The Middle East and Africa are showing growth potential due to improving healthcare infrastructure and growing awareness about the benefits of personalized medicine. Asia-Pacific showcases rapid growth in the biomarker market, facilitated by rapid economic development, increasing healthcare expenditure, and government initiatives aimed at modernizing healthcare systems. Growing populations and increasing incidence of diseases contribute to the adoption of biomarkers. Moreover, the expansion of biotechnology companies and research institutions in this region further supports the growth.
Market Insights
The market dynamics represent an ever-changing landscape of the Biomarkers Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biomarkers Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biomarkers Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Owlstone Medical's Novel Initiatives Receive the Bill & Melinda Gates Foundation Funding
Owlstone Medical has received significant financial funding from the Bill & Melinda Gates Foundation to enhance early disease detection using its innovative Breath Biopsy platform. This includes a USD 5 million equity investment and an additional USD 1.5 million in grant funding. The grant is focused on identifying volatile organic compound (VOC) biomarkers for tuberculosis (TB) and human immunodeficiency virus (HIV). [Published On: 2024-04-25]
Pioneering Research Collaboration to Enhance Treatment for Metastatic Colorectal Cancer
The National Comprehensive Cancer Network (NCCN) has collaborated with Fight Colorectal Cancer (Fight CRC) and Pfizer to provide funding aimed at advancing biomarker-directed therapies for metastatic colorectal cancer. This significant financial support is designated for innovative clinical studies that are focused on identifying and utilizing biomarkers to improve the effectiveness and precision of treatments for patients battling this advanced stage of colorectal cancer. [Published On: 2023-08-09]
FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
The U.S. Food and Drug Administration (FDA) has introduced a pivotal pilot program focused on refining the integration of specific oncology drugs with their corresponding in-vitro diagnostic tests. This initiative primarily addresses the critical use of laboratory-developed tests (LDTs) to identify specific biomarkers used for selecting cancer treatment. The program aims to establish and make public the minimum performance characteristics necessary for diagnostic tests utilized in clinical trials. [Published On: 2023-06-21]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biomarkers Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam PLC, APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., BioAgilytix, Biocrates Life Sciences AG, Biofourmis Inc., Biognosys AG, BioStarks, Charles River Laboratories, Inc., Elo Health, Inc., F. Hoffmann-La Roche, Ltd., Merck KgaA, Nightingale Health Plc, Owkin Inc., Owlstone Medical Limited, PerkinElmer, Inc., Personalis, Inc., Proteomedix AG, QIAGEN GmbH, Siemens Healthineers AG, Sino Biological Inc., Thermo Fisher Scientific, Inc., and VivoSense, Inc.
Market Segmentation & Coverage